Inter-CA collaboration Sample Clauses

Inter-CA collaboration. HealthGov will continue to lead in a number of inter-CA TWGs that have been formed during the first year. These TWGs will continue to serve as the venue where key technical areas that require inter-CA coordination are discussed and issues that affect implementation are resolved. These TWGs include Service Delivery, PhilHealth, Procurement and Logistics. And as new issues emerge that would necessitate inter-CA response new TWGs or Ad Hoc inter-CA groups will be created. HealthGov will also continue to participate and provide technical inputs to the following TWGs spearheaded by other CAs (named in brackets): Monitoring and Evaluation (HPDP), IMNCH (HPDP), HIV/AIDS (USAID/OH), CSR (PRISM); TB (TB Linc), Advocacy (Shield-ARMM) and ICV (USAID/OH). With HealthPRO now on board, it is expected that a TWG related to materials development and BCC will be formed under its leadership. The results of these various collaborations will be translated in the form of regional and provincial TA activities of HealthGov. For example, the Family Health Book that will be developed by the IMNCH TWG will be pilot tested in one of HealthGov’s project sites, Compostela Valley and Davao City. The ICV compliance monitoring tool that was developed by the ICV TWG will be integrated in the CSR TA plan for the different provinces. XxxxxxXxx also assisted the DOH and POPCOM in integrating this into the roll out of the Responsible Parenthood Movement at the LGU level. The strategic directions for the HIV/AIDS sites that were agreed upon by the HIV/AIDS TWG will serve as one of the bases for the development of the TA plan for the 12 high risk sites for HIV/AIDS covered by the project. In addition to the USAID inter-CA collaboration, HealthGov’s technical inputs to the various DOH initiated TWGs like CSR Plus, ICV and TA to the CHDs are also deemed significant especially in the development of tools and guidelines as well as in their use and field implementation. At the regional and provincial levels, HealthGov will collaborate very closely with primary and secondary stakeholders in the implementation of its TA activities. This will include activities related to identification and planning of TA to LGUs, quarterly review and scheduling of activities. Specific coordination and collaboration activities are articulated in the individual TA plans of the 23 provinces.
Sample 1
AutoNDA by SimpleDocs

Related to Inter-CA collaboration

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • AREAS OF COLLABORATION The School will collaborate under Xxxx Innovation Mission to establish, operate and support ATL in India within the school premises with financial support from NITI Aayog.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • For Product Development Projects and Project Demonstrations  Published documents, including date, title, and periodical name.  Estimated or actual energy and cost savings, and estimated statewide energy savings once market potential has been realized. Identify all assumptions used in the estimates.  Greenhouse gas and criteria emissions reductions.  Other non-energy benefits such as reliability, public safety, lower operational cost, environmental improvement, indoor environmental quality, and societal benefits.  Data on potential job creation, market potential, economic development, and increased state revenue as a result of the project.  A discussion of project product downloads from websites, and publications in technical journals.  A comparison of project expectations and performance. Discuss whether the goals and objectives of the Agreement have been met and what improvements are needed, if any.

  • Extracurricular Activities Effective July 1, 2009, stipends for participation in extracurricular activities which are authorized by the appointing authority shall be: Pathfinders/Mountaineering: Inland $950/year Sailing $400/year Art Club Advisor $300/year Drama Club Advisor $300/year Cross Country Skiing $150/year Interscholastic Coaches: Boys’ Basketball $1000/year Girls’ Basketball (if class D) $1000/year Asst. Boys’ Basketball $750/year Asst. Girls’ Basketball (if class D) $750/year Interscholastic Sport: Scorekeeper/Timekeeper $10/game Club Sport Coaches: Soccer $400/year Track $400/year Cross County Running $400/year Girls’ Basketball (if not class D) $400/year Sports Activity Director $400/year Athletic Director $200/year Committee:

  • Additional Information for Product Development Projects Outcome of product development efforts, such copyrights and license agreements. • Units sold or projected to be sold in California and outside of California. • Total annual sales or projected annual sales (in dollars) of products developed under the Agreement. • Investment dollars/follow-on private funding as a result of Energy Commission funding. • Patent numbers and applications, along with dates and brief descriptions.  Additional Information for Product Demonstrations: • Outcome of demonstrations and status of technology. • Number of similar installations. • Jobs created/retained as a result of the Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.